MedTrace Logo

LIP-01 in Hypercholesterolemia

NCT00966225 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-01-31

No results posted yet for this study

Summary

The purpose of this study is to determine a safe and tolerable dose of LIP-01

Conditions

Interventions

DIETARY_SUPPLEMENT

LIP-01

comparison of different dosages of natural health product

Sponsors & Collaborators

  • Afexa Life Sciences Inc

    lead INDUSTRY

Principal Investigators

  • Richard Lewanczuk, MD, PhD, FRCPC · University of Alberta

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966225 on ClinicalTrials.gov